Semax Purity: 1426 Lab Tests Across 653 Identified Manufacturers
74 studies on Semax curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 1,426 published third-party lab tests of Semax across 653 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.42%. Within this published corpus, 0 positive purity results were below 90%, and 24 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Semax average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.17 | $5.50–$6.50 | $1.23 | 3 sources · 3 offers |
| 10 mg | $9.00 | $5.50–$12.00 | $0.90 | 6 sources · 6 offers |
| 30 mg | $16.00 | $16.00–$16.00 | $0.53 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 1426 Semax batches across 653 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 345 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Semax
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 27 | 99.31% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound · 6 unclassified | Reveal with Pro → | |
| #2 | 16 | 99.32% | 0 of 16 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 12 | 99.52% | 0 of 12 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101335 (99.63%) · #101103 (99.85%) · #100437 (99.61%) · #100819 (99.6%) · #100830 (99.69%) · #100842 (99.9%)
Semax studies and clinical research
-
Fe-based nanocrystalline and Co-based amorphous ribbons form novel multi-layer magnetic shields
Developing advanced **magnetic shielding materials** is crucial for improving the accuracy and sensitivity of magnetic detection in diverse fields like biomedicine and fundamental physics. Multi-layer designs, especia…
-
Multi-layer Fe-nanocrystalline/Co-amorphous shields achieve 51.7 dB magnetic shielding effectiveness
A multi-layer magnetic shield combining Fe-based nanocrystalline and Co-based amorphous ribbons achieved **51.7 dB** shielding effectiveness, outperforming single-material designs.
-
Semax Peptide Shows Promise Against Prenatal Amphetamine-Induced Cognitive Deficits
-
New Software Verification Methods Enhance C Language Modularity
This research represents a substantial advancement in the field of formal software verification, particularly for the widely used C language. The ability to formally verify software components with greater precision a…
-
Semax Effectively Reduces Stress-Induced Anxiety and Depression in Rats
This study provides strong preclinical evidence for Semax's potential as a therapeutic agent for stress-induced anxiety and depression. Given that Semax is a well-studied peptide already used clinically in some countr…
-
Mexidol and Semax Protect Brain, Improve Memory After Oxygen Deprivation
These findings strongly suggest that Mexidol and Semax, particularly in combination, could be highly effective neuroprotective and cognitive-enhancing agents for conditions involving hypoxic brain injury. Their abilit…
-
Semax and PGP Peptide Show Promise for Brain Cell Recovery After Stroke
This pilot study provides compelling evidence that Semax and PGP possess significant neuroprotective and regenerative properties in the context of experimental ischemia. The ability to improve cell morphology and stim…
-
Proline Peptides Prevent Stress-Induced Blood Clotting in Rats
This research provides compelling evidence that simple proline-containing peptides can offer significant protection against stress-induced hypercoagulation, a critical factor in cardiovascular disease. The activation …
-
Semax Protects Against Blood Clotting Under Stress Conditions in Rats
This research highlights a potentially significant role for semax as a novel therapeutic agent in managing and preventing stress-induced hypercoagulation. Given that chronic physiological and psychological stress are …
-
Semax Improves Learning and Reduces Pain, Route of Administration Matters
These findings are crucial as they suggest that Semax's nootropic and analgesic effects involve distinct mechanisms and potentially different brain regions. Understanding these route-dependent differences allows for o…
-
Modified Semax Peptides Show Enhanced Stability Against Degradation
This research is significant because enhanced proteolytic stability is a critical factor for improving the pharmacokinetic profile and therapeutic efficacy of peptide-based drugs like Semax. By identifying specific N-…
-
Semax and PGP Peptides Boost Brain Repair After Ischemia in Rats
These findings highlight the significant neuroprotective potential of Semax and its fragment PGP by enhancing the brain's natural repair mechanisms following ischemic injury. By upregulating critical neurotrophins and…
-
Semax Peptide Reverses Long-Term Stress Effects from Early Life Trauma in Rats
This study provides compelling evidence that Semax can effectively reverse long-lasting behavioral and cognitive deficits induced by early life stress in rats. This highlights Semax's potential as a therapeutic agent …
-
Semax and Pro-Gly-Pro Modulate Brain Blood Vessel Genes After Stroke
This research provides compelling evidence that Semax and Pro-Gly-Pro could be promising therapeutic agents for ischemic stroke by beneficially modulating the VEGF system. Their ability to normalize detrimental gene e…
-
Semax Reduces Negative Behavioral Effects of Early Life Stress in Rats
This research highlights that Semax shows promise as a therapeutic agent for addressing behavioral and developmental deficits induced by early life stress, such as maternal deprivation. The ability of Semax to normali…
-
Nootropics Boost Exploration and Reduce Anxiety in Anxious Mouse Strain
This research provides compelling evidence that nootropic drugs can effectively improve cognitive and emotional behaviors, particularly in individuals (or in this case, mouse strains) predisposed to higher anxiety and…
-
Semax and Anti-Glutamate Antibodies Protect Brain from Ischemic Damage
This research highlights potential therapeutic strategies for mitigating the devastating effects of focal brain ischemia, particularly in critical areas like the prefrontal cortex, which is vital for executive functio…
-
Semax Peptide Accelerates Spleen Lymphoid Structure Recovery Post-Stress in Rats
This research underscores Semax's significant potential as an antistress agent, specifically in protecting vital immune organs like the spleen from stress-induced damage. Its ability to reduce macrophage proliferation…
-
Peptide Bioregulators Show Promise for Brain Protection Across Ages
This review underscores the significant therapeutic potential of peptide bioregulators for age-related neurological conditions and cognitive decline. By consolidating evidence on both complex and short peptides, it pr…
-
Early Life Drug Exposure: Lasting Brain and Behavior Changes in Rodents
The review demonstrated that neonatal injections of various pharmacological agents consistently led to detectable, long-term alterations in adult animals. These changes manifested across diverse domains, including aud…
-
Semax and PGP Boost Brain VEGF Gene Expression After Ischemia
This research highlights the neuroprotective potential of Semax and PGP by demonstrating their ability to upregulate Vegfa, a crucial factor for brain repair and recovery after ischemic injury. Enhancing Vegfa express…
-
Simple Glyprolines Show Enhanced Stability Against Degradation Compared to Semax
The enhanced proteolytic stability of simple glyprolines is a critical finding for peptide drug design, particularly for developing therapeutics that require prolonged activity or specific routes of administration. Pe…
-
Semax Modifies Immune and Vascular Gene Expression After Rat Brain Stroke
This study provides crucial insights into the molecular mechanisms underlying Semax's neuroprotective effects by demonstrating its ability to modulate gene expression related to inflammation and vascular repair after …
-
Arachidonic Acid Conjugates of Neurotropic Peptides Show Platelet Anti-Aggregation
-
Semax Peptide Binds Copper, Protects Brain Cells from Metal Toxicity
This research provides compelling evidence for the therapeutic potential of Semax as a neuroprotective agent against metal-induced toxicity, a critical factor in the pathogenesis of several debilitating neurodegenerat…
-
Semax Exhibits Dual Effects on Avoidance Learning and Memory Recovery in Rats
This research significantly reinforces the nootropic properties of Semax, demonstrating its capacity to both enhance learning in specific contexts and facilitate the recovery of learned behaviors following disruption.…
-
Semax Improves Lipid Metabolism in Psoriasis Patients with Metabolic Syndrome
This research suggests that semax could serve as a valuable adjunctive therapy for managing the lipid metabolism disturbances commonly seen in psoriasis patients with metabolic syndrome. Correcting these lipid abnorma…
-
Semax Reverses Developmental Harm from Early Antidepressant Exposure
This research provides compelling evidence for the potential of semax to act as a therapeutic intervention against neurodevelopmental issues caused by early-life exposure to SSRIs like fluvoxamine. Given the increasin…
-
Semax Peptide Protects Liver Function in Rats Under Acute and Chronic Stress
This study provides compelling evidence for the hepatoprotective potential of Semax in mitigating stress-induced liver damage and dysfunction. The peptide's ability to normalize liver enzyme activities and protein syn…
-
Semax Peptide Enhances Synaptic Communication in Spinal Cord Pain Pathways
These findings underscore Semax's profound potential to directly modulate and enhance synaptic function in neural pathways highly relevant to pain processing and overall neuronal excitability. By improving glutamaterg…
-
Semax Peptide Shows Complex, Dose-Dependent Effects on Liver Stress in Rats
This research highlights that while Semax possesses general antioxidant properties, its effects on liver enzyme markers under stress are highly nuanced and dose- and context-dependent. The finding that higher doses ca…
-
Semax Neuroprotection in Stroke May Be Mediated by Transthyretin Protein
This review significantly advances our theoretical understanding of Semax's mechanism of action, identifying transthyretin (Ttr) as a potential key mediator in its neuroprotective effects. Unraveling this specific pat…
-
Semax Protects Brain Function from Heavy Metal Damage in Rats
This study provides compelling evidence for the neuroprotective properties of Semax against heavy metal-induced cognitive impairment. Given the widespread environmental exposure to heavy metals and their significant i…
-
N-Terminus Acetylation of Semax Alters Metal Binding and Biological Activity
This study provides critical insights into how subtle chemical modifications, like N-terminus acetylation, can profoundly impact the interaction of therapeutic peptides with essential metal ions. Understanding these s…
-
Semax Peptide Mitigates Sympathetic Overactivity After Heart Attack in Rats
Sympathetic overactivity is a well-established driver of adverse cardiac events and poor prognosis following myocardial infarction. The findings that Semax peptide can moderate this activation, prevent sympathetic ner…
-
Comparing Synthetic Synacton's Activity to Natural Corticotropins
-
Semax Peptide Shows Promise for Neuroprotection and Cognitive Recovery Post-Stroke
This study provides compelling evidence that Semax possesses significant neuroprotective and cognitive-enhancing properties in a preclinical model of ischemic stroke. The observed reduction in infarct volume and impro…
-
Mexidol's Molecular Secrets Unveiled: A Chemoreactome Analysis
This chemoreactome analysis provides a comprehensive molecular blueprint for mexidol, clarifying its diverse pharmacological actions beyond its known antioxidant properties. The identification of its potential as an a…
-
Peptide ACTG4-7-PGP Protects Liver from Chronic Stress Damage in Rats
-
Unlocking Neuro-Immune Crosstalk: New Drug Targets for Inflammatory Diseases
Understanding the intricate interplay between the nervous and immune systems is critical for developing novel treatments for a wide array of chronic diseases. This review consolidates fragmented knowledge, providing a…
-
Semax Reduces Nerve Growth in Heart After Heart Attack
Semax's ability to reduce excessive and potentially detrimental sympathetic innervation growth after MI is a highly significant finding, as dysregulated nerve growth can contribute to dangerous arrhythmias and further…
-
Semax Differentially Modulates GABA and Glycine Currents in Rat Brain Neurons
-
Semax Improves Neurological Recovery in Ischemic Stroke Patients
This study provides compelling evidence that Semax can significantly enhance neurological recovery and reduce disability in ischemic stroke patients, regardless of the disease stage. The observed improvements in both …
-
Semax Modulates Brain's Default Mode Network in Healthy Adults
-
Semax Peptide Restores Immune Balance After Social Stress
This research provides experimental substantiation for Semax's role as an immunomodulator, highlighting its potential to counteract the detrimental effects of stress on the immune system. Given that chronic stress is …
-
Human iPSCs Offer Powerful New Platform for Neuroprotective Drug Screening
This novel iPSC-based platform offers a powerful, human-relevant tool for accelerating neuroprotective drug discovery, potentially reducing the reliance on less predictive animal models and improving the translatabili…
-
Peptide Drugs Deltalicin and Semax Improve Lipid Metabolism in Diabetic Rats
This study highlights the potential of peptide drugs like deltalicin as novel therapeutic agents for managing diabetic dyslipidemia. The finding that deltalicin was more potent than existing treatments suggests it cou…
-
Semax Peptide Protects Gut Microbiota from Stress in Rats
This research provides compelling evidence for a novel protective role of Semax against stress-induced alterations in gut microbiota, highlighting its potential as a therapeutic agent for maintaining gut health under …
-
Semax Peptide Shows Dual Effects on Pain Sensitivity and Analgesia
This research highlights the complex and context-dependent role of ACTH4-7-PGP (Semax) in pain modulation, moving beyond a simplistic view of its effects. Understanding this dual action could pave the way for more tar…
-
Semax Mitigates Behavioral and Brain Changes from Early Antidepressant Exposure
This study highlights the potential of Semax as a neuroprotective agent against the detrimental effects of early-life antidepressant exposure, which can lead to long-term behavioral and neurochemical deficits. Given t…
Research tools
Free, no account — handy when you're working with Semax.
